S&P boosts Hospira

Standard & Poor's said it raised its rating on Hospira Inc. to BBB+ from BBB.

The outlook is stable.

The agency said it also raised its issue-level rating on the company's senior unsecured debt to BBB+ from BBB.

"The rating on Hospira Inc. reflects its operating strength as a large, established medical products manufacturer with a broad portfolio of noncyclical and entrenched products that generate relatively stable and sustainable cash flow," said S&P credit analyst David Lugg.

"The financial risk profile is intermediate."

Risks include competitive pressures, technology risk in the medication delivery systems and supplies segment, and modest negative headwinds from the recession, the agency noted.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.